Pangborn Sensory Science Symposium

Meet some of the scientists collaborating on the research supporting the safe use of fragrance ingredients

Retrieved on: 
Wednesday, November 22, 2023

MAHWAH, N.J., Nov. 22, 2023 /PRNewswire/ -- Building upon the success of last year's event, The Research Institute for Fragrance Materials (RIFM) will hold its second virtual Annual Science Symposium on November 29, 2023, focusing on international collaborations.

Key Points: 
  • "Since its founding in 1966, RIFM has prioritized collaborative research and safety evaluation, drawing on the expertise of scientists worldwide," explains RIFM's President, Anne Marie Api.
  • "While individual scientists have made world-changing discoveries, the overwhelming majority of scientific progress is the product of cooperation, including data sharing and collaboration."
  • RIFM's Safety Assessment Manager, Danielle Botelho, concurs, "Our scientists strive to ensure the safe use of fragrances while avoiding testing on animals.
  • Our Science Symposium provides an opportunity for fragrance safety stakeholders worldwide to meet and discuss our ongoing work together with some of them."

Whipnotic® Poised to Cream the Competition: Unveiling New Brownie Batter & Peach Mango Whipped Cream Flavors!

Retrieved on: 
Thursday, September 28, 2023

Founded by two sisters, Whipnotic is the only whipped cream brand to put a colorful swirl of flavor at your fingertips, thanks to patented technology.

Key Points: 
  • Founded by two sisters, Whipnotic is the only whipped cream brand to put a colorful swirl of flavor at your fingertips, thanks to patented technology.
  • "If you're a chocolate fan, Brownie Batter is out of this world on everything from ice cream to cappuccino.
  • Brownie Batter pairs a rich, impossible-to-resist cocoa batter blend with sweet airy cream.
  • With a rapidly expanding retail footprint and a newly launched online store , Whipnotic is now available to delight whipped cream lovers nationwide.

Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology

Retrieved on: 
Tuesday, November 15, 2022

Todays publication in Frontiers in Immunology integrates data from our lab and clinical trials, along with the work of others, to describe our latest understanding of the biology of the small intestinal axis, SINTAX.

Key Points: 
  • Todays publication in Frontiers in Immunology integrates data from our lab and clinical trials, along with the work of others, to describe our latest understanding of the biology of the small intestinal axis, SINTAX.
  • We describe the observed ability of SINTAX medicines to harness natural mechanisms in the small intestine to induce regulatory T cells that can resolve inflammation throughout the body.
  • ET, to explain how these scientific advances inform and further support the development of Evelos clinical portfolio.
  • During the event, members of Evelos leadership team including Dr. Bodmer, Andrea Itano, Ph.D., Head of Research, and Duncan McHale, M.B.B.S., Ph.D., Chief Medical Officer, will discuss the scientific basis for SINTAX medicines.

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

Retrieved on: 
Thursday, October 27, 2022

CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.
  • Dr. Shiran Zimri, NeuroSense's Head of Scientific Program, will present a poster on NeuroSense's recent biomarker research, developments, and findings.
  • Dr. Niva Russek-Blum, NeuroSense' VP Discovery & IP Generator, will also attend the conference, exploring potential scientific collaborations and partnership opportunities.
  • NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.

NIAAA: Dr. Paule Joseph Selected as the Inaugural American Academy of Nursing Fellow at the National Academy of Medicine

Retrieved on: 
Wednesday, August 17, 2022

M.S., FNP-BC, FAAN, is the inaugural 2022-2024 American Academy of Nursing (AAN) Fellow at the National Academy of Medicine (NAM).

Key Points: 
  • M.S., FNP-BC, FAAN, is the inaugural 2022-2024 American Academy of Nursing (AAN) Fellow at the National Academy of Medicine (NAM).
  • Dr. Joseph 's selection will be announced in person at the Annual Meeting of the NAM in Washington, D.C. on Monday, October 17.
  • "I congratulate Dr. Joseph on her selection for this first-of-its-kind fellowship," said George F. Koob, Ph.D., Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
  • Dr. Joseph is a researcher at the NIAAA with a joint appointment at the National Institute of Nursing Research (NINR).

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Retrieved on: 
Monday, January 17, 2022

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.

Key Points: 
  • Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
  • We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board, said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics.
  • Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it, said Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics Board of Directors.
  • Elastrin Therapeutics Scientific Advisory Board is comprised of:
    Prof. Charles O'Neill, MD: Dr. ONeill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject.

Cannabis Industry Gets Back to Business--MJBizCon Returns to Las Vegas, October 19-22, 2021

Retrieved on: 
Wednesday, September 8, 2021

DENVER, Sept. 8, 2021 /PRNewswire/ -- MJBizCon returns to the Las Vegas Convention Center, October 19-22, 2021.

Key Points: 
  • DENVER, Sept. 8, 2021 /PRNewswire/ -- MJBizCon returns to the Las Vegas Convention Center, October 19-22, 2021.
  • For a decade, the cannabis industry has gathered annually at MJBizCon, making it the largest, most established cannabis business conference in the world.
  • Immediately following, are two eye-opening key panels: 'Reality Check: A Deep Dive into U.S. Cannabis LegalizationIs Your Business Prepared?'
  • The 2021 event will showcase over 1,100 exhibitors and more than 70 hours of educational content from 140 speakers.